PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation

The relevance of PCSK9 in atherosclerosis progression is demonstrated by the benefits observed in patients that have followed PCSK9-targeted therapies. The impact of these therapies is attributed to the plasma lipid-lowering effect induced when LDLR hepatic expression levels are recovered after the...

Descripción completa

Detalles Bibliográficos
Autores: Luquero, Aureli|||0000-0002-1104-5963, Badimon, Lina|||0000-0002-9162-2459, Borrell-Pages, Maria|||0000-0002-1759-9756
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:255449
Acceso en línea:https://ddd.uab.cat/record/255449
https://dx.doi.org/urn:doi:10.3389/fcvm.2021.639727
Access Level:acceso abierto
Palabra clave:Atherosclerosis
PCSK9 (proprotein convertase subtilisin kexin type 9)
Lipoprotein receptors
Inflammation
Lipid loading
LDL-cholesterol
id ES_7d15307a50a1c824c5bc176b97db7e2a
oai_identifier_str oai:ddd.uab.cat:255449
network_acronym_str ES
network_name_str España
repository_id_str
spelling PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol RegulationLuquero, Aureli|||0000-0002-1104-5963Badimon, Lina|||0000-0002-9162-2459Borrell-Pages, Maria|||0000-0002-1759-9756AtherosclerosisPCSK9 (proprotein convertase subtilisin kexin type 9)Lipoprotein receptorsInflammationLipid loadingLDL-cholesterolThe relevance of PCSK9 in atherosclerosis progression is demonstrated by the benefits observed in patients that have followed PCSK9-targeted therapies. The impact of these therapies is attributed to the plasma lipid-lowering effect induced when LDLR hepatic expression levels are recovered after the suppression of soluble PCSK9. Different studies show that PCSK9 is involved in other mechanisms that take place at different stages during atherosclerosis development. Indeed, PCSK9 regulates the expression of key receptors expressed in macrophages that contribute to lipid-loading, foam cell formation and atherosclerotic plaque formation. PCSK9 is also a regulator of vascular inflammation and its expression correlates with pro-inflammatory cytokines release, inflammatory cell recruitment and plaque destabilization. Furthermore, anti-PCSK9 approaches have demonstrated that by inhibiting PCSK9 activity, the progression of atherosclerotic disease is diminished. PCSK9 also modulates thrombosis by modifying platelets steady-state, leukocyte recruitment and clot formation. In this review we evaluate recent findings on PCSK9 functions in cardiovascular diseases beyond LDL-cholesterol plasma levels regulation.Universitat Autònoma de Barcelona 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/255449https://dx.doi.org/urn:doi:10.3389/fcvm.2021.639727reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengAgencia Estatal de Investigación https://doi.org/10.13039/501100011033 PID2019-107160RB-I00Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 CB16/11/00411Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD16/0011/018Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 FIS2020-01282Agència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2017/SGR-1480open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2554492026-06-06T12:50:31Z
dc.title.none.fl_str_mv PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
title PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
spellingShingle PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Luquero, Aureli|||0000-0002-1104-5963
Atherosclerosis
PCSK9 (proprotein convertase subtilisin kexin type 9)
Lipoprotein receptors
Inflammation
Lipid loading
LDL-cholesterol
title_short PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
title_full PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
title_fullStr PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
title_full_unstemmed PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
title_sort PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
dc.creator.none.fl_str_mv Luquero, Aureli|||0000-0002-1104-5963
Badimon, Lina|||0000-0002-9162-2459
Borrell-Pages, Maria|||0000-0002-1759-9756
author Luquero, Aureli|||0000-0002-1104-5963
author_facet Luquero, Aureli|||0000-0002-1104-5963
Badimon, Lina|||0000-0002-9162-2459
Borrell-Pages, Maria|||0000-0002-1759-9756
author_role author
author2 Badimon, Lina|||0000-0002-9162-2459
Borrell-Pages, Maria|||0000-0002-1759-9756
author2_role author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Atherosclerosis
PCSK9 (proprotein convertase subtilisin kexin type 9)
Lipoprotein receptors
Inflammation
Lipid loading
LDL-cholesterol
topic Atherosclerosis
PCSK9 (proprotein convertase subtilisin kexin type 9)
Lipoprotein receptors
Inflammation
Lipid loading
LDL-cholesterol
description The relevance of PCSK9 in atherosclerosis progression is demonstrated by the benefits observed in patients that have followed PCSK9-targeted therapies. The impact of these therapies is attributed to the plasma lipid-lowering effect induced when LDLR hepatic expression levels are recovered after the suppression of soluble PCSK9. Different studies show that PCSK9 is involved in other mechanisms that take place at different stages during atherosclerosis development. Indeed, PCSK9 regulates the expression of key receptors expressed in macrophages that contribute to lipid-loading, foam cell formation and atherosclerotic plaque formation. PCSK9 is also a regulator of vascular inflammation and its expression correlates with pro-inflammatory cytokines release, inflammatory cell recruitment and plaque destabilization. Furthermore, anti-PCSK9 approaches have demonstrated that by inhibiting PCSK9 activity, the progression of atherosclerotic disease is diminished. PCSK9 also modulates thrombosis by modifying platelets steady-state, leukocyte recruitment and clot formation. In this review we evaluate recent findings on PCSK9 functions in cardiovascular diseases beyond LDL-cholesterol plasma levels regulation.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/255449
https://dx.doi.org/urn:doi:10.3389/fcvm.2021.639727
url https://ddd.uab.cat/record/255449
https://dx.doi.org/urn:doi:10.3389/fcvm.2021.639727
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Agencia Estatal de Investigación https://doi.org/10.13039/501100011033 PID2019-107160RB-I00
Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 CB16/11/00411
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD16/0011/018
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 FIS2020-01282
Agència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2017/SGR-1480
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411637679620096
score 15,300719

Similares en LA Referencia